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Bleomycin (BLM)
, an important clinically used antitumor compound, and its analogs are challenging to prepare by chemical synthesis. Genetic engineering of the biosynthetic pathway in the producer strain would provide an efficient and convenient method of generating new derivatives of this complex molecule in vivo.
However, the BLM producing Streptomyces verticillus ATCC15003 has been refractory to all means of introducing plasmid DNA into its cells for nearly two decades.
Several years after cloning and identification of the bleomycin biosynthetic gene cluster, this study demonstrates, for the first time, genetic accessibility of this pharmaceutically relevant producer strain by intergeneric Escherichia coli -Streptomyces conjugation. Gene replacement and in-frame deletion mutants were created by λRED-mediated PCR-targeting mutagenesis and the secondary metabolite profile of the resultant mutants confirmed the identity of the BLM biosynthetic gene cluster and established its boundaries. Ultimately, the in-frame blmD deletion mutant strain S. verticillus SB5 resulted in the production of a bleomycin intermediate. The structure of this compound, decarbamoly-BLM, was elucidated and its DNA cleavage activity compared to the parent compounds.
The bleomycins (BLMs) (1, 2) are important clinically used hybrid peptide-polyketide antitumor compounds. Combined with other agents, the BLMs are used clinically for the treatment of several types of tumors and marketed under the trade name Blenoxane ® , with BLM A2 and B2 as the principle constituents (3) . Early development of drug resistance and cumulative pulmonary toxicity are the major limitations of BLMs in chemotherapy (3, 4) . Therefore, it is an important research goal to develop strategies to produce novel BLM analogs by microbial fermentation, particularly those unavailable or extremely difficult to prepare by chemical synthesis.
The BLMs are thought to exert their biological effects through a sequence selective, metal-dependent oxidative cleavage of DNA and RNA in the presence of oxygen (5, 6) . They can be dissected into four functional domains: (i) the metal-binding domain, which consists of the pyrimidoblamic acid subunit along with the adjacent β-hydroxyl histidine; (ii) the bithiazole and C-terminal amine, which confers the majority of BLM-DNA affinity; (iii) the (2S,3S,4R)-4-amino-3-hydroxy-2-methylpentanoic acid linker subunit, which plays an important role in the efficiency of DNA cleavage by BLMs; (iv) the carbamoylated disaccharide moiety (4) . The exact functional role of the sugars and the attached carbamoyl group remains controversial. They possibly contribute to cell recognition, cellular uptake of BLMs, metal-ion coordination, and/or DNA affinity (4, 6) .
The investigation of biosynthetic pathways and generation of new natural product analogs by genetic engineering critically depends on the availability of tools for recombinant DNA work in the producing organism. In general, this can be achieved by the development of an expedient genetic system for the native producer of the respective compound. Alternative solutions to this most commonly used approach are represented by the heterologous expression of the entire biosynthetic gene cluster in a suitable host strain or by the identification of genetically accessible producers of structurally closely related compounds.
While mobilization of entire biosynthetic pathways is often challenging due to their size or host specific limitations (7, 8) , producer strains of similar compounds can be found only in very few cases.
We have been studying the biosynthesis of BLM in Streptomyces verticillus ATCC15003 (9) (10) (11) (12) (13) (14) (15) (16) , and the closely related compounds tallysomycin (TLM) in Streptoalloteichus hindustanus E465-94 ATCC31158 (17) , and zorbamycin (ZBM) in Streptomyces flavoviridis ATCC21892 (18) . Feeding experiments with isotope-labeled precursors and isolation of biosynthetic intermediates suggested that the BLM aglycone is derived from nine amino acids and one acetate with methionine serving as two methyl donors (16) . Cloning and analysis of the BLM, and more recently TLM, and ZBM biosynthetic gene clusters suggested that this family of compounds is formed via a hybrid nonribosomal peptide synthetase (NRPS)-polyketide synthase (PKS) catalyzed enzymology from amino acid and carboxylic acid precursors (10, 12, 14, 17, 18) .
In spite of exhaustive efforts, S. verticillus remained refractory to all means of introducing plasmid DNA into its cells, a fact that has so far prevented us from carrying out genetic analysis of the BLM biosynthetic locus in vivo. Protoplast mediated transformation was inhibited by high lysozyme resistance of the S. verticillus mycelia as well as low frequencies of protoplast formation and regeneration, Escherichia coli-Streptomyces conjugation was complicated by poor sporulation characteristics of S. verticillus. All attempts to carry out transformation by electroporation proved to be unsuccessful. Only in one case was successful plasmid DNA transfer into S. verticillus reported by phage transduction. The plasmid, however, could not be recovered from these mutants (19) . Here we present (i) the development of a genetic system for the BLM producer S. verticillus, (ii) in vivo confirmation and boundary determination for the BLM biosynthetic gene cluster by gene inactivation in S. verticillus, and (iii) isolation of a BLM pathway intermediate, decarbamoyl-BLM, followed by its chemical and biochemical characterization. Type Culture  Collection,  Rockville,  MD,  USA) and recombinant strains generated in this study were routinely grown at 28°C in TSB liquid medium (20) . ISP4 medium supplemented with 0.05% yeast extract, 0.1% tryptone, and MgCl 2 to a final concentration of 20 mM was used to prepare S. verticillus spores and to plate out conjugation mixtures. For BLM production, S. verticillus and recombinant strains were cultured in 250-mL baffled flasks containing 50 mL of the previously described seed medium (10) for 2 days at 28°C and 250 rpm. Then, 5 mL of the seed cultures were inoculated into 250-mL baffled flasks containing 50 mL of the production medium (10) supplemented with 5 µL/50 mL 3-morpholinopropylamine (3-MOP) and fermented at 28°C and 250 rpm for 6-8 days. Escherichia coli XL1 Blue MR (Stratagene, La Jolla, CA, USA) and E. coli DH5α (21) were used for routine subcloning, plasmid preparations, and cosmid library preparation. E. coli S17-1 (20) or E. coli ET12567 (pUZ8002) (22) were the donor strains in E. coli-S. verticillus conjugation and E. coli BW25113/pIJ790 was the host for λRED-mediated PCR-targeting mutagenesis (23) .
Experimental Procedures

Bacterial strains and culture conditions-S. verticillus ATCC15003 (American
Plasmids and biochemicals-The plasmid vectors pKC1139 (24) , pKC1218 (24) , pHZ1358 (25) , pSET152 (24) , pRT801 (26) , pSOK804 (27) , pIJ773 (23), pSET151 (24) , and the aac(3)IV apramycin resistance cassette (20) were described previously. SuperCos1 (Stratagene) was used for S. verticillus cosmid library preparation and pBluescript II SK(+) (Stratagene) was employed for DNA cleavage assays. Common biochemicals, chemicals, media, restriction enzymes, and other molecular biology reagents were from standard commercial sources. Ampicillin (150 µg mL -1 ), apramycin (50 µg/mL), and chloramphenicol (25 µg/mL) were used for selection in E. coli. Apramycin (50-100 µg/mL) and thiostrepton (25-60 µg/mL) were used for selection of S. verticillus recombinants. Nalidixic acid (50 µg/mL) was used to select against the E. coli conjugal donor after conjugation.
Genetic manipulation of S. verticillus ATCC15003-E. coli-S. verticillus conjugation was carried out using a protocol based on standard literature conditions (20) . In brief, approximately 10 9 -10 10 S. verticillus spores were heat shocked in 500 µL of TSB medium supplemented with 0.4% glycine and 10.0% sucrose at 50°C for 10 min, followed by incubation at 30°C for 3-4 h as S. verticillus recipients. E. coli S17-1 containing the respective plasmid was grown in LB medium to an OD 600 of 0.4-0.6. Cells from 10 mL of culture were pelleted, washed twice with LB medium, and resuspended in 500 µL of LB medium as the E. coli donors. For conjugation, the donors (500 µL) and recipients (500 µL, 10 9 -10 10 spores) were mixed and distributed onto ISP4 plates supplemented with 0.05% yeast extract, 0.1% tryptone, and MgCl 2 to a final concentration of 20 mM. The plates were incubated at 30°C for 16-20 h, overlaid with 1 mL water containing final concentrations of 50 µg/mL nalidixic acid to select against E. coli and 100 µg/mL apramycin to select for S. verticillus exconjugants. Incubation was continued at 30°C until exconjugants appeared.
DNA isolation and manipulation-DNA isolations and manipulations in E. coli (21) and Streptomyces (20) To generate the second blmIV inactivation construct, a 22.5-kb DNA fragment containing blmIV was cloned into pSET151 and a 5.9-kb internal fragment was then replaced with the aac(3)IV gene to afford pBS42. Regions of 9.8-kb and 7.8-kb in size flanking the aac(3)IV gene at the upstream and downstream end, respectively, were available for homologous recombination.
Inactivation of blmIV (NRPS), blmVIII (PKS), blm-orf31/32 (PHNA/NRPS), blm-orf(-1) (trehalose hydrolase), and blmD (carbamoyl transferase) via λRED-mediated PCR-targeting-
The blmIV, blmVIII, blm-orf31/32, blm-orf(-1), and blmD genes located on pBS38, pBS37, pBS37, pBS40, and pBS39, respectively, were replaced by the aac(3)IV-oriT cassette from pIJ773 via λRED-mediated PCR-targeting (23) using oligonucleotide pairs blmIV-1f and blmIV-1r, blmVIII-1f and blmVIII-1r, NRPS10-1f and PHNA-1r, treh-1f and treh-1r, blmD-1f and blmD1r, respectively, to yield pBS43, pBS44, pBS45, pBS46, and pBS47, respectively. The regions flanking the aac(3)IV gene upstream and downstream were 18.9-kb and 12.9-kb for pBS43, 23.5-kb and 12.2-kb for pBS44, 6.0-kb and 33.1-kb for pBS45, 17.6-kb and ~20-kb for pBS46, and 21.0-kb and ~15-kb for pBS47.
To generate an in-frame deletion of blmD, the aac(3)IV-oriT cassette was then removed by FLP recombination from pBS47 resulting in pBS48. The bla gene on the SuperCos1 backbone of pBS48 was finally replaced by the aac(3)IV-oriT cassette from pSET152 via λRED-mediated PCRtargeting (23) using the previously described oligonucleotides f-pMT3 and r-pMT3 (17) , to yield pBS49.
Generation of the mutant strains and analysis of their secondary metabolite profile-The inactivation constructs pBS43, pBS44, pBS45, pBS46, and pBS49 were introduced into the wildtype S. verticillus strain by intergeneric conjugation. Exconjugants were selected by a combination of the apramycin-resistant phenotype and PCR screening using oligonucleotide pairs blmIV-2f and blmIV-2r for pBS43, blmVIII-2f and blmVIII-2r for pBS44, C-PHNA-f1 and C-PHNA-r1 for pBS45, C-treh-f1 and C-treh-r1 for pBS46, as well as C-blmD-f2 and C-blmD-r for pBS49, respectively, affording the mutant strains S. verticillus SB1, SB2, SB3, SB4, and SB5 ( Fig.  1 and Fig. S1 , Supplemental Data). Suitable probes were PCR amplified using oligonucleotide pairs blmIII/IVprobe-f and blmIII/IVprobe-r for SB1, blmVIIIprobe-f and blmVIIIprobe-r for SB2, C-PHNA-f1 and C-PHNA-r1 for SB3 (only a 1.446-kb BamHI fragment of the 2.788-kb PCR product was used as probe), Treh-p-f1 and Treh-pr1 for SB4, and C-blmE-f2 and C-blmE-r for SB5. The genotypes of all apparent double crossover mutant strains were further confirmed by Southern blot analyses ( Fig. 1 and Fig. S1 , Supplemental Data).
The mutants were cultured and investigated for BLM production with the wildtype S. verticillus strain as a control ( Isolation and analysis of BLM and decarbamoyl-BLM-BLM and decarbamoyl-BLM were first isolated as Cu-complexes. Cu-free BLM and decarbamoyl-BLM were obtained by treating the Cu-complexes with 0.5 M EDTA-Na (pH 7.3) solution. The identity of BLM was confirmed by LC-ESI mass spectrometry on an Agilent 1100 HPLC-MSD SL quadrupole mass spectrometer. Nucleotide sequence accession number-The nucleotide sequences reported in this study are available in the GenBank database under accession numbers L26955, AF210249, and EU805703.
RESULTS
Development of a genetic system for S. verticillus
ATCC15003-Aiming at the establishment of a genetic system for the BLM producer, the growth and sporulation conditions were evaluated and optimized. S. verticilllus grows optimally between 28°C and 30°C. Common media such as TSB, ISP2, and R2YE (20) are suitable for vegetative growth of S. verticillus. However, for genomic DNA isolation, it is necessary to supplement TSB with 10% (wt/vol) sucrose and 0.4% (wt/vol) glycine to facilitate lysozyme digestion. SGGP medium (29) supplemented with 10% or 20% (wt/vol) sucrose and YEME medium (20) supplemented with 34% (wt/vol) sucrose proved most suitable for protoplast preparation. S. verticillus sporulates very poorly on common growth media such as TSB, ISP2, R2YE, and CM medium. Slightly green spore formation to an acceptable extent (~10 7 spores/plate) was observed after 10 days of growth at 30°C on ISP4 medium or ISP4 medium supplemented with 0.05% yeast extract, 0.1% tryptone, and MgCl 2 to a final concentration of 20 mM. The BLM producer is fairly sensitive to apramycin, thiostrepton, and kanamycin, but fully resistant to even high concentrations (up to 200 µg/mL) of hygromycin; therefore, 50-150 µg/mL of apramycin and 25-60 µg/mL of thiostrepton were used throughout this study for selection.
Intergeneric conjugation allowed the introduction of two out of six plasmid vectors, pSET152 and pRT801, into S. verticillus. Although S. verticillus mycelium of the early exponential growth phase can be protoplasted in a respectable yield (20-30%), the protoplasts cannot be regenerated efficiently under all conditions tested (≤10%). All attempts to introduce plasmid DNA into S. verticillus by protoplast-mediated transformation failed to produce any true transformants, and this technique was subsequently abandoned. In contrast, we were successful in developing a protocol for conjugation between E. coli S17-1 and S. verticillus. Following a literature procedure (20) with modifications, we found that conjugation between E. coli S17-1 and S. verticillus occurred with the highest frequency on modified ISP-4 agar freshly supplemented with 20 mM MgCl 2 when 10 9 -10 10 S. verticillus recipient cells and E. coli S17-1 donor cells harvested from 10 mL of culture grown to an OD 600 of 0.4-0.6 were used. Utilization of the methylation deficient E. coli ET12567/pUZ8002 as donor strain failed to result in higher exconjugant frequencies than the methylation proficient E. coli S17-1. The true nature of exconjugants was verified by PCR and Southern blot hybridization.
Self-replicating plasmids derived from three different replicons (the temperature sensitive pSG5 derivative pKC1139 (24) , the SCP2* derivative pKC1218 (24) , and the pIJ101 derivative pHZ1358 (25) ) and integrative vectors derived from three different bacteriophages (the φC31 derived pSET152 (24), the phiBT1 derived pRT801 (26) , and the VWB derived pSOK804 (27) ) were tested in a series of E. coli -S. verticillus intergeneric conjugation experiments. All replicative vectors and one of the integrative vectors, pSOK804, failed to yield any true exconjugants.
The highest conjugation frequencies were obtained with pSET152 and pRT801 at 10 -7 -10 -8 exconjugants/cfu. Homologous recombination in S. verticillus ATCC15003-Gene replacement for blmIV and blmVIII via double-crossover homologous recombination was carried out to confirm, for the first time, the identity of the BLM biosynthetic gene cluster by gene inactivation. Construct pBS41, which contains a 6.4-kb fragment of blmIV separated into a 4.1-kb upstream and a 2.3-kb downstream region by the insertion of the aac(3)IV apramycin resistance gene, was first chosen for this experiment. Construct pBS42, which harbors a 9.8-kb upstream and 7.8-kb downstream fragment was also generated for homologous recombination. No true exconjugants were obtained after conjugal transfer of these plasmids into S. verticillus.
A newly prepared cosmid library of S. verticillus genomic DNA was then employed for gene inactivation by λRED-mediated PCRtargeting mutagenesis (23) . Replacement of the nonribosomal peptide synthetase (NRPS) encoding blmIV gene by the aac(3)IV gene on pBS38 generated an 18.9-kb upstream and a 12.9-kb downstream flanking region accessible for homologous recombination in pBS43 (Fig. 1A) . Similarly, inactivation of the polyketide synthase (PKS) encoding blmVIII gene on pBS37 yielded 23.5-kb upstream and 12.2-kb downstream regions in pBS44 (Fig. 1C) . After introduction of pBS43 and pBS44 into S. verticillus by conjugation, exconjugants resistant to apramycin were isolated and the double crossover mutants SB1 and SB2, respectively, were selected ( Fig. 1B  and 1D ). Both mutant strains completely lost their ability to produce BLM (Fig. 2 , traces IV and III), confirming that the NRPS encoding blmIV and the PKS encoding blmVIII are indeed required for BLM biosynthesis. The conjugation frequencies observed for both inactivation constructs were in the same range as for the integrative model plasmid pSET152 (10 -7 -10 -8 exconjugants/cfu).
Determination of the boundaries for the BLM biosynthetic locus by gene inactivation-Through inactivation of selected genes [blm-orf31/32 and blm-orf(-1)]
residing at distal ends of the BLM biosynthetic gene cluster, the upstream and downstream blm cluster boundaries were assigned to reside between blm-orf31/32 and blm-orf30 and between blm-orf7 and blm-orf(-1), respectively (Fig. S2, Supporting Information) .
At the upstream end of the cluster, blm-orf30 and blmorf29 had previously been proposed to play a role in regulatory and self-resistance mechanisms in BLM production, respectively (10) . The predicted gene products of blm-orf31 (a protein with similarity to phosphonoacetate hydrolases) and blm-orf32 (an NRPS protein) were thought to be dispensible for BLM biosynthesis. Gene replacement of blm-orf31 together with part of blm-orf32 yielded the mutant strain SB3 that exhibited BLM production levels similar to the wild-type S. verticillus strain (~95% of the wildtype strain; Fig. 2, traces II and I) .
At the downstream boundary, blm-orf7 encoding a transport protein with a possible function in BLM resistance mechanisms of the producer strain represented the last gene of the sequenced region (accession number L26955) (28) . Sequencing and analysis of ~5.4-kb beyond the published nucleotide sequence revealed a ~3.2-kb gap without any apparent ORFs downstream of blm-orf7 followed by blm-orf(-1). The blm-orf(-1) gene product (802 aa) exhibits high similarity to hydrolases such as a putative glycosyl hydrolase from Streptomyces ambofaciens (accession number CAJ88378; 67% identity and 76% similarity) and a hypothetical protein from Streptomyces coelicolor (accession number NP_624928; 68% identity and 76% similarity). Inactivation of blm-orf(-1) yielded the mutant strain SB4 that had little effect on BLM production (~95% of the wild-type strain; Fig. 2 , traces VI and I), confirming that its product is not required for BLM biosynthesis.
In-frame deletion of blmD resulting in the accumulation of a pathway intermediateInactivation of the blmD gene resulted in the accumulation of a pathway intermediate, decarbamoyl-BLM, which was characterized by mass spectrometric (MS) and nuclear magnetic resonance (NMR) spectroscopic analyses. In frame deletion was chosen for the inactivation of the carbamoyl transferase encoding blmD gene. This strategy ensures the generation of non-polar mutants, in contrast to gene replacement mutants bearing an antibiotic resistance cassette. The selected double crossover mutant, SB5, completely lost its ability to produce BLM and instead accumulated a new compound, decarbamoly-BLM, with a slightly different retention time (Fig. 2, traces V and I ). This new compound (6-8 mg/L) was isolated and the pure intermediate (10.0 mg) was obtained as a Cucomplex. The decarbamoly-BLM-Cu complex was further treated with EDTA to remove Cu and subsequently subjected to HPLC on a C18 column to afford the Cu-free molecule (8.0 mg) as a pale white powder.
Structure elucidation of the intact molecule of 3-MOP-decarbamoyl-BLM was carried out by a combination of MS along with 1 H, 13 C, and 2D NMR spectroscopic analyses, as well as by comparing the resultant NMR data with those reported in the literature, particularly of BLM A2 (30) (Fig. 3) . Upon ESI-MS analysis, the 3-MOPdecarbamoyl-BLM-Cu complex yielded a molecular ion peak (m/z) at 729. 4 13 C NMR spectrum appeared to lack two signals (C 54 ) relative to the total carbon number proposed for the molecular formula of 3-MOP-decarbamoyl-BLM by HRMS (C 56 H 85 N 17 O 21 S 2 ) due to the symmetric structure of the morpholino ring. The signals at δ C 55.0 and δ C 67.7, however, were approximately twice as high as the ordinary carbon signals suggesting that these two signals represent the symmetric carbons of the morpholino ring. Analyses of 1 H-1 H COSY and TOCSY spectra lead to the partial structures of C2-C3, C5-C6, C13-C14, C32-C31-C33-C34-C35, C39-C38-C37, C41-C42, C51-C52-C53, C54,57-C55,56, and two sugar moieties, which were subsequently connected using HMBC correlations (Fig. 4) . The 1 H and 13 C NMR spectra of 3-MOPdecarbamoyl-BLM are almost identical to the ones of BLM except that (i) they lack the signals from the carbamoyl carbonyl group (C26) attached to the disaccharide moiety of BLM, and (ii) the signals attributed to the 3-MOP [δ H 3.50, δ C 39.8 (C51), δ H 2.02, δ C 27.1 (C52), δ H 2.96, δ C 58.0 (C53), δ H 3.03, δ C 55.0 (C54,57), δ H 3.89, δ C 67.7 (C55,56)] differed from the signals obtained with the BLM A2 amine (30) (Fig. 3) . The C-21, 22, and 23 of the mannosyl moiety of 3-MOPdecarbamoyl-BLM clearly showed a des-acylation shift compared to those signals of BLM (Δδ H22 = -0.92, Δδ C21 = +1.5, Δδ C22 = -4.2, and Δδ C23 = +2.0 with Δδ defined as Δδ = δ 3-MOP-decarbamoyl-BLM - δ BLM ).
These data suggested that the isolated intermediate represents 3-MOP-decarbamoyl-BLM and confirmed BlmD as the carbamoyl transferase.
DNA cleavage activity of decarbamoyl-BLMLoss of the carbamoyl group attached to the BLM-disaccharide resulted in a decrease in DNA cleavage activity by a factor of ten. Decarbamoyl-BLM was compared to BLM A2 and B2 for its ability to cleave pBluescript II SK(+) supercoiled plasmid DNA in the presence of Fe 2+ . BLM mediated single-strand cleavage first results in the conversion of supercoiled plasmid DNA (form A) to open-circular plasmid DNA (form B), and double-strand cleavage subsequently generates linearized plasmid DNA (form C). In this assay, BLM A2 and B2 showed nearly 100% plasmid relaxation and ~50% plasmid linearization at concentrations of 1 µM each while decarbamoyl-BLM exhibited ~10-fold reduced DNA cleavage activity, resulting in a mixture of supercoiled, relaxed, and linearized plasmid DNA at a concentration of 5 µM (Fig. 5) . The observed DNA cleavage activity was concentration dependent for all the compounds tested.
DISCUSSION
More than four decades after the discovery of the clinically important anticancer compound BLM (1), its native producer S. verticillus unambiguously proved genetically accessible for the first time. Although some improvement of protoplast formation and regeneration was achieved during these studies, DNA transfer by protoplast mediated transformation failed to yield any true transformants. Intergeneric E. coliStreptomyces conjugation under optimized conditions, however, facilitated the development of a genetic system for this pharmaceutically important microorganism.
From an entire set of six different replicative and integrative vectors employed as test plasmids, two out of three integrative vectors, pSET152 and pRT801, yielded true exconjugants at frequencies of 10 -7 -10 -8 exconjugants/cfu, which is 10 5 -10 6 -fold lower than reported for Streptomyces lividans (~10 -2 exconjugants/cfu) under similar conditions (31) . Failure to introduce the self-replicating vectors originating from three different Streptomyces replicons indicated that this host strain is unable to propagate any of the well known E. coli-Streptomyces shuttle vectors, thereby significantly complicating expression and complementation experiments in this strain. Typically, the frequency of site-specific integration into the host chromosome is much higher than that of homologous recombination for a specific Streptomyces strain. Based on the observation of site-specific integration frequencies as low as 10 -7 -10 -8 exconjugants/cfu for S. verticillus, failure to obtain gene inactivation mutants by homologous recombination was not surprising. Since the frequency for homologous recombination is also proportional to the size of the DNA regions available for the recombination event (20) , a recently developed technology (λRED-mediated PCR-targeting mutagenesis) (23) provided a promising new strategy to genetically modify this strain allowing the facile increase of inactivation constructs. As opposed to 2.3-kb and 4.1-kb homologous arms and 9.8-kb and 7.8-kb homologous arms in the earlier constructs pBS41 and pBS42, respectively, flanking regions of >12-kb on at least one side of the targeted gene in constructs pBS43, pBS44, pBS45, pBS46, and pBS49 enabled the generation of the desired mutant strains at surprisingly high frequencies, very comparable to site specific integration of pSET152 and pRT801. From these data we conclude that for S. verticillus, the minimal size range of DNA fragments allowing for homologous recombination events to occur lies between 10-kb and 12-kb, which is uncommonly large compared to other Streptomyces strains (20) .
To date, many other microbial producers of important natural products have been reported to be genetically inaccessible or extremely hard to manipulate (32) (33) (34) . However, the availability of an efficient genetic system is one of the key prerequisites for successful engineering of natural product biosynthetic pathways to generate new biologically active derivatives using combinatorial biosynthesis.
The results from our studies indicate a potential solution for this widely experienced obstacle in microbiology, especially in cases where the alternative approach of heterologously expressing the desired biosynthetic pathway has failed or is not feasible.
Multiple gene knockout experiments by gene replacement and in-frame deletion confirmed the identity of the BLM biosynthetic locus in vivo, experimentally defined the BLM cluster boundaries, and revealed new insights into the timing of BLM-carbamoylation by BlmD. Five gene inactivation experiments proved the involvement of blmIV, blmVIII, and blmD in BLM biosynthesis and confirmed the predicted cluster boundaries to be located downstream of blmorf31/32 and upstream of blm-orf(-1). All gene replacement mutants showed either the expected BLM producing phenotype for targeted genes located outside the cluster boundaries (blmorf31/32
and blm-orf(-1)) or complete abolishment of BLM production for genes proposed to be involved in BLM biosynthesis (blmIV and blmVIII). Only the in-frame deletion of blmD, however, yielded the anticipated pathway intermediate, decarbamoyl-BLM. It may be speculated that early pathway intermediates stay tethered to their respective NRPS or PKS enzyme and therefore could not be isolated from the respective mutant fermentations. Moreover, intermediates lacking the sugar moiety may not be recognized by the respective transport proteins for their export out of the cells and hence escape detection in the culture broth. Isolation of 3-MOP-decarbamoyl-BLM from the cell free supernatant of the respective fermentations, in contrast, indicates efficient transport of late biosynthetic intermediates into the production media. A one step purification procedure using Amberlite IRC-50 resin (H + type), allowed us to estimate the titer of 3-MOP-decarbamoyl BLM to be 6-8 mg/L representing approximately 70% of the 3-MOP-BLM production observed in wild type S. verticillus (8-10 mg/L) under equivalent fermentation conditions. The 3-MOPdecarbamoyl BLM was then purified from preparative scale fermentation.
Extensive analysis of MS, 1 H, 13 C, 1 H-1 H COSY, TOCSY, HSQC, and HMBC data for this compound resulted in the full 1 H and 13 C NMR spectroscopic assignments (Fig. 4 , Table. 1) and their comparison to the BLM A2 spectroscopic data reported in the literature (30) confirmed that the isolated intermediate indeed represents 3-MOP-decarbamoyl-BLM.
Decarbamoyl-BLM has previously been reported as a partial hydrolysis product of BLM under basic aqueous conditions after prolonged storage, but has only been accessible in very small quantities (35, 36) . Additionally, decarbamoyl-BLM demethyl-A2, lacking one methyl group in the A2 terminal amine, was isolated as a byproduct during the tedious multi-step total chemical synthesis of BLM demethyl-A2 (37) . From a structural point of view, the carbamoyl group has been speculated to represent one of the ligands involved in formation of the active metal complexed BLM. Detailed mechanistic investigations, however, have so far been hampered by the limited availability of decarbamoyl-BLM. The accessibility of this particularly important compound in large quantities by simple fermentation and compound isolation procedures from the mutant of a highly appreciated, pharmaceutically relevant Streptomyces strain now facilitates such studies.
Our data presented here support the hypothesis that carbamoylation is the final step of BLM biosynthesis, revising the previous assumptions for disaccharide formation and attachment (Fig. 6 ) (10). This is in agreement with the novobiocin biosynthetic pathway for which carbamoylation of the noviose sugar was also reported to be the final catalytic step (38) . The previously discussed alternative of the mannose moiety first being carbamoylated by BlmD and then transferred onto the BLM-monosaccharide by the respective glycosyltransferase (BlmE or BlmF) seems less likely, since this pathway would require broad substrate flexibility of the glycosyltransferase in order to catalyze decarbamoyl-mannose transfer to form 3-MOP-decarbamoly-BLM in the blmD defective mutant strain.
Investigation of 3-MOP-decarbamoly-BLM for DNA relaxation and linearization in comparison to BLM A2 and B2 indicates an important role of the carbamoyl group for efficient cleavage activity. Although several in vitro studies have shown that deglyco-BLMs exhibit reduced DNA cleavage activities compared to BLM A2 or B2 (36, 39, 40) , the role of the carbamoyl group remained controversial. Decarbamoyl-BLM was reported to show significantly reduced malondialdehyde forming activity but similar oligonucleotide cleavage activity compared to BLM A2 (36) , similar DNA cleavage activity as BLM in the presence of Fe 2+ , but reduced activity in the presence of Cu 2+ and dithiothreitol (39) , and oligonucleotide cleavage activities much closer to deglyco-BLM A2 rather than BLM A2 (41) . Our results obtained with 3-MOP-decarbamoyl-BLM, however, indicate a significant impact of the carbamoyl group on DNA cleavage activity resulting in ~10-fold reduced plasmid relaxation efficiency compared to BLM A2 and B2. This observation may originate from the carbamoyl group directly contributing to the coordination of the metal ion for DNA cleavage or from being involved in DNA binding. Although there has been speculation about the former hypothesis (41), the latter is supported by the recently published crystal structure of DNA-bound Co(III)-BLM B2; the carbamoyl NH 2 forms a hydrogen bond with the minor grove, while the function of the disaccharide seems to be to correctly position and stabilize the entire complex (42) . In addition to the likely reduced DNA affinity of 3-MOPdecarbamoly-BLM caused by the lack of the carbamoyl group, the different terminal amines of 3-MOP-decarbamoly-BLM, BLM A2, and B2 may also contribute to the variation in DNA cleavage activity. In depth spectroscopic and mechanistic studies of 3-MOP-decarbamoyl-BLM in comparison to BLM will now allow elucidation of the exact contribution of the carbamoyl group to DNA binding, cleavage activity, cytotoxicity, and bioavailability of the BLM family of compounds.
In summary, since the identification and sequence analysis of the BLM biosynthetic gene cluster several years ago (10, 12, 14) , the inaccessibility of S. verticillus to genetic manipulation has prevented us from in depth in vivo investigations of its biosynthetic pathway. Moreover, all attempts to express the entire ~65-kb BLM biosynthetic gene cluster in a heterologous host and to engineer the respective DNA sequence therein have been unsuccessful as well. Although progress in genetic manipulation of the related TLM and ZBM producers has been made recently (17, 18) , this study represents the first report of a new BLM derivative generated in vivo by engineering of the respective producer strain and demonstrates the feasibility of BLM analog production in suitable mutants on a large scale in the future. Moreover, the availability of an S. verticillus mutant strain producing 3-MOPdecarbamoyl-BLM in respectable yields will now greatly facilitate spectroscopic and mechanistic studies, providing insight into the exact mode of action of the BLM family of antibiotics. Tables S1, S2 , and S3 for plasmids, bacterial strains, and oligonucleotides, respectively, used in this study; Figure S1 for a schematic presentation of the determination of the blm gene cluster boundaries by gene inactivation, isolation and confirmation of the resultant mutant strains (SB3 and SB4); and Figure S2 depicting the blm gene cluster. This material is available free of charge via the Internet at http://www.jbc.org. 
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